Form 4: Fulgent Genetics Insider Sells Shares for Tax Withholding

Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a transaction involving the withholding of 1,645 shares to cover tax obligations upon the vesting of restricted stock units.

Summary

• Hanlin Gao, Chief Scientific Officer at Fulgent Genetics, Inc., engaged in a transaction on April 26, 2026.
• This transaction involved the withholding of 1,645 shares of common stock.
• The shares were withheld to satisfy tax obligations arising from the vesting of restricted stock units.
• These restricted stock units were assumed under a merger agreement dated November 7, 2022.
• Following this transaction, Mr. Gao beneficially owns 993,007 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard tax-related stock withholding transaction by an insider, rather than a strategic financial event.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions, such as the one reported by Fulgent Genetics' Chief Scientific Officer, and are standard practice for publicly traded companies to maintain transparency regarding ownership changes.

Stakeholder Impact

• Shareholders: The transaction does not indicate a change in beneficial ownership for tax purposes, as the shares were withheld to cover tax obligations, not sold on the open market. The total beneficial ownership remains largely unchanged from a net perspective, though the form details the direct ownership post-withholding.

Key Dates

Keywords

Fulgent Genetics, FLGT, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Tax Obligations, Merger Agreement, Beneficial Ownership